Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms

Full text
Author(s):
Scopim-Ribeiro, Renata [1, 2] ; Machado-Neto, Joao Agostinho [2, 1] ; Campos, Paula de Melo [2] ; Niemann, Fernanda Soares [2] ; Lorand-Metze, Irene [2] ; Costa, Fernando Ferreira [2] ; Olalla Saad, Sara Teresinha [2] ; Traina, Fabiola [1, 2]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Sch Med, Dept Internal Med, BR-14049 Ribeirao Preto, SP - Brazil
[2] Univ Estadual Campinas, Hemoctr Unicamp, Inst Nacl Ciencia & Tecnol Sangue, Hematol & Hemotherapy Ctr, Rua Carlos Chagas 480, BR-13083878 Campinas, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: DIAGNOSTIC PATHOLOGY; v. 11, MAR 16 2016.
Web of Science Citations: 4
Abstract

Background: New sequencing technologies have enabled the identification of mutations in Ten-eleven-translocation 2 (TET2), an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) in myeloid neoplasms. We have recently identified reduced TET2 mRNA expression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which is associated with a poor overall survival in MDS. We herein aimed to investigate TET2 mutations and their impact on TET2 expression in a cohort of patients with myeloid neoplasms, including MDS and AML patients. Findings: TET2 mutations were observed in 8 out of 19 patients (42 %) with myeloid neoplasms. The TET2 expression profile was similar between in wild type and in TET2 mutated patients. Conclusion: Our results suggest that TET2 expression is reduced in MDS/AML patients, independently of mutational status. (AU)

FAPESP's process: 12/09982-8 - Investigation of molecular alterations in myeloid neoplasms
Grantee:Fabíola Traina
Support type: Regular Research Grants
FAPESP's process: 11/51959-0 - Biology of neoplastic diseases of bone marrow
Grantee:Sara Teresinha Olalla Saad
Support type: Research Projects - Thematic Grants
FAPESP's process: 11/15905-3 - DNMT3a mutations, expression and function in myelodysplasic syndromes and acute myeloid leukemia
Grantee:Renata Scopim Ribeiro
Support type: Scholarships in Brazil - Master